Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2023 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) of incorporation or organization) Delaware 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address o ...

Delaware 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) of incorporation or organization) For the quarterly period ended September 30, 2023 (Exact name of Company as specified in its charter) Table of Contents Commission File Number: 001-36081 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q NANOVIRICIDES, INC. QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 1 Controls Drive Shelton, Connecticut 06484 (Address ...

Financial Performance - For the year ended June 30, 2023, the company reported a net loss of approximately $8,589,000, compared to a net loss of approximately $8,107,000 for the year ended June 30, 2022, reflecting an increase of $482,000 attributed to higher license milestone expenses [507]. - The company has an accumulated deficit of approximately $131,081,000 as of June 30, 2023, with no revenues generated and no revenues anticipated in the foreseeable future [515]. - The company has not generated any revenues since its inception in May 2005 and does not expect to generate revenues in the near future [500]. - Interest income increased to approximately $356,000 for the year ended June 30, 2023, compared to approximately $12,000 for the year ended June 30, 2022, due to higher interest rates [504]. - The company has approximately $2,034,000 in liabilities as of June 30, 2023, compared to approximately $413,000 as of June 30, 2022 [514]. Cash and Funding - As of June 30, 2023, the company had approximately $8,150,000 in cash and cash equivalents, down from approximately $14,066,000 as of June 30, 2022 [514]. - The Company has approximately $8,150,000 in cash and cash equivalents, expected to fund operations through October 2024 [516]. - The Company has filed a registration statement allowing for the sale of up to $150 million in various securities, with the entire amount still available for sale [518]. - The Company anticipates needing additional funding for later stages of human clinical trials unless a partnership with a larger pharmaceutical company is formed [521]. - The Company intends to seek non-dilutive financing, grants, and pharmaceutical partnerships as its drug candidates progress [532]. Research and Development - Research and development expenses increased to approximately $6,392,000 for the year ended June 30, 2023, up from approximately $5,785,000 for the year ended June 30, 2022, primarily due to increased license fees [503]. - The Company plans to file an IND for its Shingles Skin Cream after advancing its pan-coronavirus and RSV program drugs into clinical trials [511]. - The Company plans to file an IND for the Shingles Skin Cream after advancing its pan-coronavirus and RSV programs into clinical trials [517]. - The estimated costs for Phase I clinical trials are approximately $1.5 million, $5 million for Phase II, and $10 million for Phase III, assuming successful prior phases [522]. - The planned recruitment for Phase 1a/1b clinical trials includes 36 healthy volunteers and 36 COVID patients [524]. - The Company has limited experience in pharmaceutical drug development, leading to potential inaccuracies in budget estimates [526]. - The Company is classified as a clinical drug development stage company and will continue until regulatory approvals are obtained [533]. Strategic Partnerships - The company has signed several cooperative research and development agreements with TheraCour and expects to enter into additional agreements with other entities [509]. - The company plans to actively pursue co-development and licensing agreements with other pharmaceutical companies to enhance revenue opportunities [497]. - The Company believes its market capitalization will improve as its coronavirus program matures through human clinical trials [523].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) of incorporation or organization) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address of pri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2022 Commission File Number: 001-36081 (Exact name of Company as specified in its charter) of incorporation or organization) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address of principal executive ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) of incorporation or organization) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address of p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2022 Commission File Number 001-36081 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) (State or other jurisdiction of incorporation or NEVADA 76-0674577 (I.R.S. Employer Identification No.) organization) 1 CONTROLS DRIVE, SHELTON, CONNECTICUT, 06484 (Address of principal execu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) of incorporation or organization) 1 Controls Drive Shelton, Connecticut 06484 (Address of princ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) of incorporation or organization) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address of principal executive offices and zip code) (203) 937 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such f ...